Illumina (ILMN)
(Delayed Data from NSDQ)
$139.02 USD
+10.04 (7.78%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $139.40 +0.38 (0.27%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$139.02 USD
+10.04 (7.78%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $139.40 +0.38 (0.27%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Zacks News
New Strong Sell Stocks for January 14th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
Myriad Genetics (MYGN), Illumina Partner to Enhance Oncology Arm
by Zacks Equity Research
Myriad Genetics (MYGN) partners with Illumina to expand the access as well as extend the reach of myChoice CDx through its services offering in the international market.
Illumina (ILMN), Helix Partner to Develop Tracking Setup in U.S.
by Zacks Equity Research
Illumina (ILMN) collaborates with Helix with support from the CDC to set up an enhanced surveillance infrastructure to track the emergence and prevalence of B.1.1.7.
Here's Why You Should Hold on to Illumina (ILMN) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Illumina (ILMN), backed by its focus on partnerships and worldwide expansion to drive growth.
Illumina (ILMN)-Harvard Pilgrim Partner to Expand WGS Access
by Zacks Equity Research
Illumina (ILMN) signs agreement to expand the availability of WGS to enable faster and cost-effective diagnosis of genetic diseases in children.
Scottish Warlords of Investing: Baillie Gifford Sells TSLA, Buys TTD, Holds SHOP
by Kevin Cook
They didn't want to sell Tesla ever, but their profits were just to enormous.
Here's Why You Should Hold on to Illumina (ILMN) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Illumina (ILMN), backed by its focus on partnerships and worldwide expansion to drive growth.
Illumina (ILMN) Q3 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
Illumina (ILMN) exhibits dismal segmental performance in the third quarter of 2020 due to pandemic-led business disruptions.
Illumina (ILMN) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Illumina (ILMN) delivered earnings and revenue surprises of 32.47% and 10.15%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com featured highlights include: StoneCo, Las Vegas Sands, Yandex and Illumina
by Zacks Equity Research
Zacks.com featured highlights include: StoneCo, Las Vegas Sands, Yandex and Illumina
4 Toxic Stocks That You Need to be Wary of & Dump Right Now
by Rimmi Singhi
If you own toxic stocks for a long period of time, you are sure to see huge erosion in your wealth. Figuring out such stocks and selling them at the right time is the key to successful investing.
CHRS or ILMN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CHRS vs. ILMN: Which Stock Is the Better Value Option?
Illumina (ILMN) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Illumina (ILMN) is upbeat about its third-quarter sequencing consumable revenue growth.
Analysts Estimate Illumina (ILMN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
7 Diagnostic and Genomic Stocks Storming Into October
by Kevin Cook
COVID-19 has created an Apollo Mission status for advanced medical technologies and smart investors are profiting.
Stock Market News for Sep 25, 2020
by Zacks Equity Research
Benchmarks closed in the positive territory on Thursday as tech stocks recovered some of the recent losses along with reports of a new stimulus bill in the making by House Democrats.
ANIK vs. ILMN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ANIK vs. ILMN: Which Stock Is the Better Value Option?
Company News for Sep 22, 2020
by Zacks Equity Research
Companies in the news are: MSFT, ROKU, NKLA, ILMN
Illumina-CDGN Partner to Create Coronavirus Tracking System
by Zacks Equity Research
Illumina (ILMN) partners with Australia's CDGN to track the national transmission of the virus causing COVID-19.
Zacks.com featured highlights include: ILMN, PFSW, CCJ and BMRN
by Zacks Equity Research
Zacks.com featured highlights include: ILMN, PFSW, CCJ and BMRN
These 4 Stocks Could Be Toxic for Your Portfolio
by Rimmi Singhi
Toxic stocks are sure to result in loss for investors over time. Figuring out such stocks on a consistent basis and discarding them at the right time is the key to successful investing.
Why Is Illumina (ILMN) Down 14.3% Since Last Earnings Report?
by Zacks Equity Research
Illumina (ILMN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Crocs, Illumina, Microsoft, Walmart and Oracle highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Crocs, Illumina, Microsoft, Walmart and Oracle highlighted as Zacks Bull and Bear of the Day
Bear of the Day: Illumina (ILMN)
by Madeleine Johnson
The coronavirus pandemic has dampened this medical stock's earnings and outlook.
LGND vs. ILMN: Which Stock Is the Better Value Option?
by Zacks Equity Research
LGND vs. ILMN: Which Stock Is the Better Value Option?